SAN DIEGO, Dec. 20, 2016 - /PRNewswire/ -- ResMed (NYSE: RMD) today announced that industry leader Carlos M. Nunez, MD, will become ResMed's chief medical officer, effective January 3, 2017.
Nunez most recently served as senior vice president of medical
affairs for Becton, Dickinson and Company. He will be based in ResMed's San Diego headquarters and will report directly to CEO Mick Farrell and President/COO Rob Douglas.
"I'm delighted to welcome Carlos Nunez
to ResMed," said Farrell. "Carlos has great depth in clinical and
medical technology, and great breadth in healthcare informatics and
business management. His proven leadership capabilities and track record
of collaboration across global teams make him an ideal addition to our
executive team. Carlos will play a key role in accelerating ResMed's
2020 growth strategy, including clinical trials of sleep apnea,
neuromuscular disease and COPD, as well as in connected care."
Dr. Nunez joins ResMed with two decades of leadership experience in
the medical field, with a focus on aligning the clinical realities of
modern healthcare with the business strategies of global enterprises. As
senior vice president of medical affairs for BD, he drove business
strategy, innovation and public policy efforts across a business with $12 billion
in revenue, while advising on safety, quality and regulatory matters.
He has also held senior leadership positions at United HealthCare
Group's Optum division, CareFusion and Picis, a healthcare informatics
company.
"As an industry leader in the treatment of sleep-disordered
breathing, chronic obstructive pulmonary disease and other chronic
diseases, ResMed is tackling some of society's largest healthcare
challenges with a unique mixture of top-quality devices and software,"
said Dr. Nunez. "I'm looking forward to working with ResMed's global
team to translate emerging clinical research into the next wave of
products, services, and solutions that even better treat chronic
respiratory diseases, keep patients out of the hospital, save time and
money for providers and payers, and ultimately improve patient
outcomes."
ResMed's current chief medical officer, Dr. Glenn Richards,
will transition to the role of medical director for the company's
product development teams. Dr. Richards will continue to provide
clinical support and leverage his vast experience to create even greater
value for ResMed customers and their patients.
"Glenn is a pioneer in the field of sleep medicine and has led our
global medical team with passion and dedication. He has helped as we
have evolved ResMed from the world's leading respiratory medical device
company to our position today as the world's leading tech-driven medical
device company," said Mick Farrell.
"We are grateful for Glenn's hard work and his contributions to ResMed
and the field of respiratory medicine over more than two decades. Our
team is thrilled that Glenn will continue to help steward ResMed's
medical path forward in his new role as medical director."
Additional Background on Carlos Nunez, MD
Dr. Nunez led medical affairs for Becton Dickinson
and Company's medical segment since 2015. Before that, he was the chief
medical officer and SVP medical affairs for CareFusion, a global
medical technology company specializing in acute respiratory care,
reducing medication errors and the prevention of healthcare-associated
infections. During this time, he built and led a multidisciplinary team
that provided medical authority and oversight for all of the businesses
and functions of the multinational medical device and pharmaceutical
company. From 2000 to 2010, Nunez was the chief physician executive for
medical informatics company Picis, Inc. While at Picis, he provided
medical leadership and clinical direction for corporate strategy,
marketing, product development, sales, implementation and customer
relations in both domestic and international markets. Before that, he
was the director of critical care education and research at Carolinas
Medical Center Northeast in Concord, North Carolina. Nunez is a board-certified anesthesiologist. He received his MD from the University of Miami's Leonard M. Miller School of Medicine where he also completed his postgraduate training in anesthesiology, critical care medicine and clinical research.
About ResMed
ResMed (NYSE:RMD) changes lives with
award-winning medical devices and cutting-edge cloud-based software
applications that better diagnose, treat and manage sleep apnea, chronic
obstructive pulmonary disease (COPD) and other chronic diseases. ResMed
is a global leader in connected care, with more than 2 million patients
remotely monitored every day. Our 5,000-strong team is committed to
creating the world's best tech-driven medical device company – improving
quality of life, reducing the impact of chronic disease, and saving
healthcare costs in more than 100 countries.
ResMed.com | Facebook | Twitte
|
For media:
|
For investors:
|
|
Alison Graves
|
Agnes Lee
|
|
Director, Corporate Communications
|
Senior Director, Investor Relations
|
|
O: 858-836-6789
|
O: 858-836-5971
|
FONTE ResMed Inc.
0 Comentarios